Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Medical Solutions Group Regulatory News (AMS)

Share Price Information for Advanced Medical Solutions Group (AMS)

Share Price is delayed by 15 minutes
Get Live Data
219.00    2.00 (0.92%)
Bid:
218.50
Ask:
219.50
Spread: 1.00 (0.458%)
Market Cap: £475.74m
AMS Live PriceLast checked at - London Stock Exchange

Intraday Advanced Medical Solutions Group Share Chart

Rule 2.9 Announcement

8 Jun 2026 14:25

RNS Number : 4477H
Advanced Medical Solutions Grp PLC
08 June 2026
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

FOR IMMEDIATE RELEASE

8 June 2026

 

Advanced Medical Solutions Group plc("AMS")

 

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of The City Code on Takeovers and Mergers (the "Code"), AMS confirms that, as at the date and time of this announcement, it had 220,435,551 ordinary shares of 5 pence each in issue and admitted to trading on the AIM Market of the London Stock Exchange. AMS does not hold any ordinary shares in treasury. Therefore, the total number of shares with full voting rights in AMS at the above date was 220,435,551.

The International Securities Identification Number (ISIN) for AMS' ordinary shares is GB0004536594 and AMS' LEI number is 213800HJP6OWOSZI1L74.

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Tel: +44 (0) 1606 545508

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTUWUORNUUNRAR
Date   Source Headline
4th Sep 20237:00 amRNSTrading Statement
31st Aug 20235:56 pmRNSTotal Voting Rights
10th Aug 20237:00 amRNSNotice of Interim Results
31st Jul 20234:51 pmRNSTotal Voting Rights
11th Jul 20237:00 amRNSHalf Year Trading Update
30th Jun 20232:14 pmRNSTotal Voting Rights
19th Jun 202312:18 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSUS regulatory approval granted for LiquiBandFix8®
31st May 20232:08 pmRNSResults of Annual General Meeting
31st May 20237:00 amRNSAnnual General Meeting
22nd May 20236:13 pmRNSDirector/PDMR Shareholding
28th Apr 20235:57 pmRNSTotal Voting Rights
26th Apr 20235:37 pmRNSAnnual Report and Notice of Annual General Meeting
18th Apr 20236:22 pmRNSDirector/PDMR Shareholding
3rd Apr 202312:41 pmRNSTotal Voting Rights
27th Mar 20235:56 pmRNSDirector/PDMR and PCA Shareholding
22nd Mar 20235:52 pmRNSDirector/PDMR Shareholding
15th Mar 20237:00 amRNSUnaudited Preliminary Results
8th Mar 20232:56 pmRNSBlock listing announcement
28th Feb 20235:56 pmRNSTotal Voting Rights
14th Feb 20237:01 amRNSNotice of Results
1st Feb 20231:30 pmRNSAcquisition of Connexicon Medical
31st Jan 20233:17 pmRNSTotal Voting Rights
10th Jan 20237:00 amRNSFull Year Trading Update
3rd Jan 20237:00 amRNSTotal Voting Rights
30th Nov 20226:04 pmRNSTotal Voting Rights
28th Nov 20224:20 pmRNSChange of Registrar
31st Oct 20227:00 amRNSLiquiBandFix8® PMA application accepted by FDA
14th Sep 20227:00 amRNSInterim Results
8th Sep 20224:53 pmRNSBlock listing announcement
17th Aug 20227:00 amRNSNotice of Interim Results
1st Aug 20227:00 amRNSDirectorate Change
6th Jul 20227:00 amRNSHalf Year Trading Update
8th Jun 20221:52 pmRNSResults of Annual General Meeting
8th Jun 20227:00 amRNSAnnual General Meeting
31st May 20224:03 pmRNSTotal Voting Rights
25th May 20227:00 amRNSAMS announces US approval for LiquiBand® XL
13th May 20226:08 pmRNSDirector- PDMR Dealing Announcement
29th Apr 20225:43 pmRNSAnnual Report, Notice of AGM and Board Change
21st Apr 20225:30 pmRNSDirector/PDMR Shareholding
23rd Mar 20223:46 pmRNSDirector/PDMR and PCA Shareholding
16th Mar 20227:00 amRNSUnaudited Preliminary Results
9th Mar 20221:17 pmRNSBlock listing Interim Review
7th Mar 20227:00 amRNSNotice of Results
31st Dec 202112:43 pmRNSTotal Voting Rights
16th Dec 20217:00 amRNSFull Year Trading Update
30th Nov 20214:14 pmRNSTotal Voting Rights
4th Nov 20217:00 amRNSAppointment of Adviser
29th Oct 202111:35 amRNSTotal Voting Rights
11th Oct 20213:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.